Sarepta Therapeutics (0L35) Ratios
Sarepta Therapeutics Ratios
GB:0L35's free cash flow for Q2 2026 was $-8.25M. For the 2026 fiscal year, GB:0L35's free cash flow was decreased by $-2.64M and operating cash flow was $-5.61M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 2.32 | 4.20 | 3.95 | 4.13 | 5.75 |
| Quick Ratio | 1.48 | 3.18 | 3.45 | 3.80 | 5.34 |
| Cash Ratio | 0.73 | 1.51 | 0.66 | 1.56 | 4.67 |
| Solvency Ratio | -0.30 | 0.11 | -0.20 | -0.24 | -0.17 |
| Operating Cash Flow Ratio | -0.19 | -0.28 | -0.77 | -0.53 | -0.98 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | -4.75 | 0.00 | 0.00 |
| Net Current Asset Value | $ 328.86M | $ 638.03M | $ 174.09M | $ -185.56M | $ 384.13M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.31 | 0.34 | 0.43 | 0.52 | 0.37 |
| Debt-to-Equity Ratio | 0.91 | 0.88 | 1.63 | 4.20 | 1.24 |
| Debt-to-Capital Ratio | 0.48 | 0.47 | 0.62 | 0.81 | 0.55 |
| Long-Term Debt-to-Capital Ratio | 0.42 | 0.43 | 0.57 | 0.80 | 0.54 |
| Financial Leverage Ratio | 2.94 | 2.59 | 3.80 | 8.13 | 3.39 |
| Debt Service Coverage Ratio | -67.74 | 15.84 | -3.68 | -11.43 | -4.99 |
| Interest Coverage Ratio | -67.60 | 11.86 | -12.17 | -10.07 | -7.24 |
| Debt to Market Cap | 0.37 | 0.10 | 0.14 | 0.14 | 0.15 |
| Interest Debt Per Share | 10.01 | 14.32 | 15.36 | 19.08 | 14.98 |
| Net Debt to EBITDA | -0.37 | 0.76 | -2.13 | -1.09 | 3.03 |
| Profitability Margins | |||||
| Gross Profit Margin | 59.90% | 83.22% | 87.91% | 85.00% | 86.17% |
| EBIT Margin | -31.50% | 14.68% | -40.06% | -68.24% | -50.64% |
| EBITDA Margin | -29.48% | 16.66% | -36.49% | -63.76% | -45.22% |
| Operating Profit Margin | -29.92% | 11.47% | -21.54% | -57.47% | -65.50% |
| Pretax Profit Margin | -31.94% | 13.71% | -41.83% | -73.95% | -59.69% |
| Net Profit Margin | -32.45% | 12.37% | -43.11% | -75.40% | -59.66% |
| Continuous Operations Profit Margin | -32.45% | 12.37% | -43.11% | -75.40% | -59.66% |
| Net Income Per EBT | 101.59% | 90.21% | 103.05% | 101.96% | 99.96% |
| EBT Per EBIT | 106.76% | 119.58% | 194.19% | 128.68% | 91.13% |
| Return on Assets (ROA) | -21.30% | 5.94% | -16.42% | -22.49% | -13.30% |
| Return on Equity (ROE) | -62.55% | 15.40% | -62.37% | -182.75% | -45.13% |
| Return on Capital Employed (ROCE) | -29.18% | 6.75% | -10.26% | -21.37% | -17.06% |
| Return on Invested Capital (ROIC) | -29.03% | 6.06% | -9.80% | -21.24% | -16.95% |
| Return on Tangible Assets | -21.48% | 5.98% | -16.57% | -22.54% | -13.36% |
| Earnings Yield | -31.63% | 2.03% | -6.02% | -6.20% | -5.72% |
| Efficiency Ratios | |||||
| Receivables Turnover | 4.23 | 2.93 | 2.85 | 3.57 | 4.06 |
| Payables Turnover | 3.14 | 1.49 | 0.91 | 1.46 | 1.26 |
| Inventory Turnover | 0.96 | 0.43 | 0.47 | 0.69 | 0.52 |
| Fixed Asset Turnover | 4.67 | 3.89 | 3.48 | 3.81 | 2.97 |
| Asset Turnover | 0.66 | 0.48 | 0.38 | 0.30 | 0.22 |
| Working Capital Turnover Ratio | 1.16 | 0.89 | 0.64 | 0.46 | 0.33 |
| Cash Conversion Cycle | 348.75 | 737.24 | 511.73 | 384.18 | 501.55 |
| Days of Sales Outstanding | 86.28 | 124.69 | 128.28 | 102.34 | 89.83 |
| Days of Inventory Outstanding | 378.76 | 857.84 | 783.83 | 531.82 | 700.34 |
| Days of Payables Outstanding | 116.29 | 245.29 | 400.38 | 249.98 | 288.62 |
| Operating Cycle | 465.04 | 982.52 | 912.11 | 634.15 | 790.17 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -1.96 | -2.16 | -5.42 | -3.72 | -5.45 |
| Free Cash Flow Per Share | -2.93 | -3.71 | -6.37 | -4.08 | -5.93 |
| Dividend Paid and CapEx Coverage Ratio | -2.02 | -1.40 | -5.74 | -10.09 | -11.51 |
| Capital Expenditure Coverage Ratio | -2.02 | -1.40 | -5.74 | -10.09 | -11.51 |
| Operating Cash Flow Coverage Ratio | -0.20 | -0.15 | -0.36 | -0.20 | -0.38 |
| Operating Cash Flow to Sales Ratio | -0.09 | -0.11 | -0.40 | -0.35 | -0.63 |
| Free Cash Flow Yield | -13.63% | -3.05% | -6.60% | -3.15% | -6.58% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -3.02 | 49.23 | -16.62 | -16.13 | -17.47 |
| Price-to-Sales (P/S) Ratio | 1.03 | 6.08 | 7.17 | 12.16 | 10.43 |
| Price-to-Book (P/B) Ratio | 1.98 | 7.57 | 10.37 | 29.47 | 7.89 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -7.33 | -32.77 | -15.14 | -31.73 | -15.19 |
| Price-to-Operating Cash Flow Ratio | -10.98 | -56.18 | -17.78 | -34.87 | -16.51 |
| Price-to-Earnings Growth (PEG) Ratio | 0.01 | -0.35 | 0.60 | -0.29 | 0.63 |
| Enterprise Value Multiple | -3.85 | 37.24 | -21.77 | -20.17 | -20.02 |
| Enterprise Value | 2.49B | 11.80B | 9.88B | 12.00B | 6.36B |
| EV to EBITDA | -3.85 | 37.24 | -21.77 | -20.17 | -20.02 |
| EV to Sales | 1.13 | 6.20 | 7.95 | 12.86 | 9.05 |
| EV to Free Cash Flow | -8.11 | -33.45 | -16.79 | -33.55 | -13.19 |
| EV to Operating Cash Flow | -12.14 | -57.34 | -19.72 | -36.87 | -14.34 |
| Tangible Book Value Per Share | 10.61 | 15.79 | 8.98 | 4.31 | 11.24 |
| Shareholders’ Equity Per Share | 10.88 | 16.07 | 9.30 | 4.40 | 11.42 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.02 | 0.10 | -0.03 | -0.02 | 0.00 |
| Revenue Per Share | 20.98 | 20.01 | 13.46 | 10.66 | 8.64 |
| Net Income Per Share | -6.81 | 2.47 | -5.80 | -8.03 | -5.15 |
| Tax Burden | 1.02 | 0.90 | 1.03 | 1.02 | 1.00 |
| Interest Burden | 1.01 | 0.93 | 1.04 | 1.08 | 1.18 |
| Research & Development to Revenue | 0.69 | 0.42 | 0.71 | 0.94 | 1.10 |
| SG&A to Revenue | 0.22 | 0.29 | 0.39 | 0.48 | 0.40 |
| Stock-Based Compensation to Revenue | 0.06 | 0.10 | 0.15 | 0.25 | 0.16 |
| Income Quality | 0.29 | -0.87 | 0.93 | 0.46 | 1.06 |
Currency in USD